 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Undiscovered and Profitable Biotech with significant upside potential ..Many new attractive Product launches and approvals expected within this year . Cipher Pharmaceuticals (CPH.T) Market Cap: $39.7 Million CAD Cash $10.4 Million CAD Price: $1.46 Shares Out: 26.8 Million Slide Presentation filecache.investorroom.com Cipher anticipates several key milestones in 2019 that will continue to enhance long term value, including: Xydalba launch in first half of 2019 DTR-001 pre-clinical results in Q2 2019 Regulatory approval for plecanatide from Health Canada in Q4 2019 Regulatory approval for A-101 from Health Canada in Q4 2019 Top line results for MOB-015 Phase 3 study in North America expected in late Q4 2019 Largest Shareholder : John Douglas Mull, MD 9,911,265 Grandeur Peak Global Advisors LLC 1,522,200 Taylor Asset Management, Inc. (Canada) 243,100 Harold Morton Wolkin, CFA 184,134 Arthur M. Deboeck 104,300 Mark A. Beaudet 87,790 Christian Godin 39,009 Robert D. Tessarolo 37,013 Stephen L. Lemieux, CPA 25,008 Acadian Asset Management LLC 9,093 
| ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |